Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: J Immunol. 2020 May 1;204(9):2321–2328. doi: 10.4049/jimmunol.1901343

Figure 1. Spectrum of p53-based immunotherapy of cancer.

Figure 1.

A) Timeline for application of p53 Meth A antigen for cancer immunotherapy. There was a significant delay between the initial discovery in 1979 and its application beginning in 1993. B) A wide spectrum of vaccines has been introduced for clinical use that involve dendritic cells, viruses or chemical adjuvants as vehicles for p53-based immunizations that are aimed at inducing anti-p53 immune responses in cancer patients.